Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP101 plus gemcitabine versus placebo plus gemcitabine in first-line advanced pancreatic adenocarcinoma
NL-OMON31980Phase 2Active, not recruiting
- Sponsor
- SciClone Pharmaceuticals (Holdings) Limited
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing RP101 + gemcitabine with Placebo + gemcitabine (2 arms). Primary endpoint: Overall survival. Started Oct 2008; status: active, not recruiting.
02
Drugs
brivudine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON31980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31980.